PDF(Pubmed)
Abstract：
Photodynamic therapy (PDT) has been a topic of interest since the first report in 1900 but has yet to become a \'mainstream\' treatment protocol in the medical field. There are clear indications for which PDT might be the \'method of choice\', but it is unlikely that there will be protocols for the treatment of systemic disease. This report discusses recent developments for promoting PDT efficacy, in the context of what is already known. Factors that can limit the scope of these applications are also indicated. Among the more interesting of these developments is the use of formulation techniques to target specific organelles for photodamage. This can enhance responses to PDT and circumvent situations where an impaired death pathway interferes with PDT efficacy.
摘要：
自1900年的第一份报告以来，光动力疗法（PDT）一直是人们感兴趣的话题，但尚未成为医学领域的“主流”治疗方案。有明确的迹象表明，PDT可能是“选择的方法”，但是不太可能有治疗全身性疾病的方案。本报告讨论了促进PDT疗效的最新进展，在已知的背景下。还指出了可能限制这些应用范围的因素。这些发展中更有趣的是使用配制技术来靶向特定的细胞器以光损伤。这可以增强对PDT的反应并避免受损的死亡途径干扰PDT功效的情况。
